Disease activity-dependent expression of nerve growth factor TRKA and P75 receptors on elevated dendritic cells and peripheral leucocytes in patients with systemic lupus erythematosus

Lupus ◽  
2020 ◽  
Vol 29 (8) ◽  
pp. 970-975 ◽  
Author(s):  
Stefanie Welle ◽  
Anna M Wolf ◽  
Christian Dernbach ◽  
Ute Klarmann-Schulz ◽  
Matthias F Seidel
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Dendritic Cells ◽  
Nerve Growth Factor ◽  
Growth Factor ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Inflammatory Diseases ◽  
Receptor Expression ◽  
Systemic Lupus ◽  
Nerve Growth

Introduction The nervous system modulates rheumatic diseases in neurogenic inflammation (NI). Nerve growth factor (NGF) plays a pivotal role in NI and chronic nociceptive pain. However, the role of NGF in autoimmune inflammatory diseases is not well understood. The aim of this study was to analyse NGF high- (TrkA) and low-affinity (p75) receptors on all major leucocyte subsets of patients with systemic lupus erythematosus (SLE) as a potential indicator of NI. Methods A total of 13 patients were analysed by fluorescence-activated cell sorting and compared to 13 healthy control (HC) subjects. Patients were also stratified for high or low disease activity (CRP, ESR, SLEDAI, ANA, anti-dsDNA and C3/C4). Statistics included the Kruskal–Wallis test and Mann–Whitney U-test. Results When comparing patients and HC, TrkA was not differentially expressed. In contrast, p75 was increased on CD16+ and CD56+ leucocytes in patients. CD11c+ dendritic cells (DC) were in total increased in SLE. DCs were also significantly elevated in active patients. Furthermore, we found an intermediate CD11b+ population strongly expressing TrkA in patients and HC. Conclusion We demonstrate for the first time differential NGF receptor expression in SLE. The increased CD11c+ DCs might indicate additional activation in SLE.

NERVE GROWTH FACTOR IN SERUM OF CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS IS CORRELATED WITH DISEASE ACTIVITY

Cytokine ◽  
2002 ◽  
Vol 20 (3) ◽  
pp. 136-139 ◽  
Author(s):  
Kristiina Aalto ◽  
Laura Korhonen ◽  
Pekka Lahdenne ◽  
Pirkko Pelkonen ◽  
Dan Lindholm
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Nerve Growth Factor ◽  
Growth Factor ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Nerve Growth

Modification of lymphoid and brain nerve growth factor levels in systemic lupus erythematosus mice

1996 ◽  
Vol 204 (1-2) ◽  
pp. 13-16 ◽  
Author(s):  
Luisa Bracci-Laudiero ◽  
Thomas Lundeberg ◽  
Carina Stenfors ◽  
Elvar Theodorsson ◽  
Paola Tirassa ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Nerve Growth Factor ◽  
Growth Factor ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Nerve Growth

scholarly journals Dendritic cells’ characteristics in patients with treated systemic lupus erythematosus

2020 ◽  
Author(s):  
Anna Wardowska ◽  
Żaneta Smoleńska ◽  
Katarzyna A. Lisowska ◽  
Zbigniew Zdrojewski ◽  
Michał Pikuła
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Dendritic Cells ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Complement Components ◽  
Expression Of Genes ◽  
Luminex Technology ◽  
Transcriptional Changes ◽  
Chronic Autoimmune Disease

The systemic lupus erythematosus (SLE) is a chronic autoimmune disease related to a loss of immune tolerance against autoantigens that leads to tissue inflammation and organ dysfunction. Constant stimulation of dendritic cells (DC) with autoantigens is hypothesized to increase the B cells’ activity which are involved in production of autoantibodies that play an essential role in the SLE development. We focused our study on detecting alterations in DCs at the cellular and molecular levels in patients with treated SLE, depending on the disease activity and treatment. In order to phenotype subpopulations of DCs, multicolor flow cytometry was used. Transcriptional changes were identified with quantitative PCR, while soluble cytokine receptors were assessed with the Luminex technology. We show that SLE patients display a higher percentage of activated myeloid DCs (mDCs) when compared to healthy people. Both, the mDCs and plasmacytoid DCs (pDCs) of SLE patients were characterized by changes in expression of genes associated with their maturation, functioning and signalling, which was especially reflected by low expression of regulatory factor ID2 and increased expression of IRF5. pDCs of SLE patients also showed increased expression of IRF1. There were also significant changes in the expression of APRIL, MBD2, and E2-2 in mDCs that significantly correlated with some serum components, i.e. anti-dsDNA antibodies or complement components. However, we did not find any significant differences depending on the disease activity. While the majority of available studies focuses mainly on the role of pDCs in the disease development, our results show significant disturbances in the functioning of mDCs in SLE patients, thus confirming mDCs’ importance in SLE pathogenesis.

Levels of Transforming Growth Factor-β Are Low in Systemic Lupus Erythematosus Patients with Active Disease

2010 ◽  
Vol 37 (10) ◽  
pp. 2039-2045 ◽  
Author(s):  
ANDREA BECKER-MEROK ◽  
GRO ØSTLI EILERTSEN ◽  
JOHANNES C. NOSSENT
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Growth Factor ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Transforming Growth Factor ◽  
Lymphocyte Subsets ◽  
Concomitant Treatment ◽  
Systemic Lupus ◽  
Cell Counts ◽  
Tgf Β1

Objective.Cytokines are central regulators of the immune response but the workings of this complex network in systemic lupus erythematosus (SLE) are not fully understood. We investigated a range of inflammatory and immune-modulating cytokines to determine their value as biomarkers for disease subsets in SLE.Methods.This was a cross-sectional study in 102 patients with SLE (87% women, disease duration 10.6 yrs). Circulating concentrations of interleukin 1β (IL-1β), IL-4, IL-6, IL-10, IL-12, IL-17, monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein 1 (MIP-1α), MIP-1β, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and total transforming growth factor-β1 (TGF-β1) were related to disease activity (SLE Disease Activity Index; SLEDAI), lymphocyte subsets, autoantibody levels, accrued damage (Systemic Lupus International Collaborating Clinics/ACR Damage Index; SDI), and concomitant treatment.Results.Patients with SLE had lower levels of TGF-β1 (p = 0.01) and IL-1β (p = 0.0004) compared to controls. TGF-β1 levels were lower in patients with SLEDAI scores 1–10 and SDI > 3; and were correlated with CD4+, CD8+, and natural killer cell counts; and were independent of steroid or cytotoxic drug use. Treatment with cardiovascular drugs was associated with lower IL-12 levels. No consistent disease associations existed for the other cytokines investigated.Conclusion.Lower TGF-β1 was the most consistent cytokine abnormality in patients with SLE. The associations with disease activity, lymphocyte subsets, and damage suggest that TGF-β1 may be a therapeutic target of interest in SLE.

Sign in / Sign up

Export Citation Format

Share Document